Advertisement

Digestive Diseases and Sciences

, Volume 57, Issue 3, pp 806–812 | Cite as

Incidence and Risk Factors of Hepatocellular Carcinoma Recurrence After Liver Transplantation in the MELD Era

  • Pratima Sharma
  • Kathy Welch
  • Hero Hussain
  • Shawn J. Pelletier
  • Robert J. Fontana
  • Jorge Marrero
  • Robert M. Merion
Original Article

Abstract

Background and Aims

Deceased donor liver transplantation (DDLT) rates for candidates with hepatocellular carcinoma (HCC) have significantly increased in the MELD era because of the extra priority given to these candidates. We examined the incidence and pre-DDLT radiological and donor factors associated with post-DDLT HCC recurrence in the MELD era.

Methods

Outcomes of HCC candidates aged ≥18 years that underwent DDLT between 2/28/02 and 6/30/08 (n = 94) were reviewed. The primary outcome was biopsy-proven post-LT HCC recurrence at any site. Kaplan–Meier analysis was used to calculate the cumulative incidence and Cox regression was used to identify the predictors of post-LT HCC recurrence.

Results

The median age of the 94 candidates who met the study criteria was 54 years, 64% had hepatitis C, median lab MELD was 13, and median pre-LT AFP was 47 ng/dl. Based upon pre-DDLT imaging, 94% candidates met the Milan criteria. The median waiting time to transplant was 47 days and 27% received pre-DDLT loco-regional therapy. Seventeen (18%) developed HCC recurrence after 2.1 median years with a cumulative incidence of 6.8, 12, and 19% at 1, 2, and 3 years post-DDLT. The pre-DDLT number of lesions (p = 0.015), largest lesion diameter (p = 0.008), and higher donor age (p = 0.002) were the significant predictors of HCC recurrence after adjusting for pre-LT loco-regional therapy and waiting time. Post-LT HCC recurrence (p < 0.0001) and higher donor age (p = 0.029) were associated with lower post-LT survival.

Conclusions

Post-LT HCC recurrence is higher in our MELD era cohort than the reported rate of 8% at 4 years in Mazzaferro et al.’s study. The risk of HCC recurrence was significantly associated with the number of lesions and size of the largest lesion at the time of DDLT as well as with older donor age. Risk stratification using a predictive model for post-LT HCC recurrence based on pre-LT imaging and donor factors may help guide candidate selection and tailoring of HCC surveillance strategies after LT.

Keywords

Hepatocellular carcinoma Deceased donor liver transplantation Model for end-stage liver disease 

Abbreviations

DDLT

Deceased donor liver transplantation

HCC

Hepatocellular carcinoma

IOC

Index of concordance

MELD

Model for end-stage liver disease

Notes

Acknowledgments

Dr. Pratima Sharma was supported by an American Society of Transplantation/Roche clinical science faculty development grant for 2008 and Michigan Institute for Clinical and Health Research NIH-CTSA, UL1RR024986, Collaborative Type 2 (Bedside to community) grant. Dr. Sharma is also supported by National Institutes of Health grant KO8 DK-088946. This research was presented, in part, as a free communication at the American Transplant Congress, 2010, held in San Diego, California.

References

  1. 1.
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699.PubMedCrossRefGoogle Scholar
  2. 2.
    Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R. Results of the first year of the new liver allocation plan. Liver Transpl. 2004;10:7–15.PubMedCrossRefGoogle Scholar
  3. 3.
    Sharma P, Balan V, Hernandez JL, et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl. 2004;10:36–41.PubMedCrossRefGoogle Scholar
  4. 4.
    Sharma P, Harper AM, Hernandez JL, et al. Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation. Am J Transplant. 2006;6:1957–1962.PubMedCrossRefGoogle Scholar
  5. 5.
    Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 1992;16:132–137.PubMedCrossRefGoogle Scholar
  6. 6.
    UNOS/OPTN. 3.6 Organ distribution: allocation of livers. In: Policies; 2002. http://www.unos.org/PoliciesandBylaws/policies/pdfs/policy_8.pdf.
  7. 7.
    Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.PubMedCrossRefGoogle Scholar
  8. 8.
    Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–387.PubMedCrossRefGoogle Scholar
  9. 9.
    Kremers WK. Concordance for survival time data: fixed and time-dependent covariates and possible ties in predictor and time: Mayo Clinic Foundation; 2007.Google Scholar
  10. 10.
    Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7:2587–2596.PubMedCrossRefGoogle Scholar
  11. 11.
    Toso C, Trotter J, Wei A, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2008;14:1107–1115.PubMedCrossRefGoogle Scholar
  12. 12.
    Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002;8:765–774.PubMedCrossRefGoogle Scholar
  13. 13.
    Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database. Hepatology. 2009;49:832–838.PubMedCrossRefGoogle Scholar
  14. 14.
    Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology. 2008;134:1342–1351.PubMedCrossRefGoogle Scholar
  15. 15.
    Fisher RA, Kulik LM, Freise CE, et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant. 2007;7:1601–1608.PubMedCrossRefGoogle Scholar
  16. 16.
    Zimmerman MA, Trotter JF, Wachs M, et al. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl Int. 2007;20:747–753.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Pratima Sharma
    • 1
    • 5
  • Kathy Welch
    • 2
  • Hero Hussain
    • 4
  • Shawn J. Pelletier
    • 3
  • Robert J. Fontana
    • 1
  • Jorge Marrero
    • 1
  • Robert M. Merion
    • 3
  1. 1.Department of Internal MedicineUniversity of MichiganAnn ArborUSA
  2. 2.Department of BiostatisticsUniversity of MichiganAnn ArborUSA
  3. 3.Department of SurgeryUniversity of MichiganAnn ArborUSA
  4. 4.Department of RadiologyUniversity of MichiganAnn ArborUSA
  5. 5.Division of Gastroenterology, Department of Internal MedicineUniversity of Michigan Health SystemAnn ArborUSA

Personalised recommendations